scispace - formally typeset
J

Julio Rosenstock

Researcher at University of Texas Southwestern Medical Center

Publications -  423
Citations -  39792

Julio Rosenstock is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 94, co-authored 364 publications receiving 32784 citations. Previous affiliations of Julio Rosenstock include Medical City Dallas Hospital & Pfizer.

Papers
More filters

Original Article: Treatment Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

Robert E. Ratner, +2 more
TL;DR: Dose–response relationships were seen for once- and twice-daily regimens, with similar efficacy levels, with a 20 lg once-daily dose of lixisenatide demonstrating the best efficacy-to-tolerability ratio.
Journal ArticleDOI

Effects of Canagliflozin Added on to Basal Insulin +/– Other Antihyperglycemic Agents in Type 2 Diabetes

Richard Dumas, +6 more
- 01 Oct 2013 - 
Journal ArticleDOI

Efficacy and safety of rosiglitazone combined with glibenclamide is effective and well tolerated in type 2 diabetes patients inadequately controlled on maximum-dose glibenclamide

Julio Rosenstock, +4 more
- 01 Sep 2000 - 
Journal ArticleDOI

Signals and Noise in Drug Safety Analyses The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance

William T. Cefalu, +3 more
- 01 Jul 2013 - 
TL;DR: In this issue of Diabetes Care, the editorial team has decided to “push the envelope” by openly addressing a safety issue in drug development and monitoring that is gaining interest and provoking controversy: the ongoing debate on the risks versus benefits of incretin-based therapies.
Journal ArticleDOI

Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist.

Hertzel C. Gerstein, +9 more
- 01 Feb 2021 - 
TL;DR: The effect of the weekly exendin‐based glucagon‐like peptide‐1 receptor agonist efpeglenatide on cardiovascular outcomes in high‐risk patients with type 2 diabetes with and without chronic kidney disease (CKD) is unknown.